Boehringer Ingelheim Pharmaceuticals, Inc. drugs

26 results

  • cyltezo - adalimumab - adbm

    (Adalimumab-Adbm)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    Cyltezo is a TNF blocker indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, non-infectious uveitis in adults, and juvenile idiopathic arthritis and uveitis in pediatric patients.
    Medication Details
    Drug Interactions

  • gilotrif - afatinib tablet, film coated

    (Afatinib)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    Gilotrif treats metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations as first-line therapy, and metastatic squamous NSCLC that has progressed after platinum-based chemotherapy.
    Medication Details
    Drug Interactions

  • glyxambi - empagliflozin and linagliptin tablet, film coated

    (Empagliflozin And Linagliptin)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    GLYXAMBI (empagliflozin/linagliptin) is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. Empagliflozin also reduces the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
    Medication Details
    Drug Interactions

  • jardiance - empagliflozin tablet, film coated

    (Empagliflozin)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    Jardiance reduces the risk of cardiovascular death and heart failure hospitalization in adults. It also slows chronic kidney disease progression, reduces cardiovascular death in type 2 diabetes with established cardiovascular disease, and improves blood sugar control in adults and children aged 10+ with type 2 diabetes.
    Medication Details
    Drug Interactions